Nonetheless, evaluation of pembrolizumab in breast cancer is ongoing, with some promising clinical activity in PD-L1 positive estrogen receptor (ER) + breast cancer based on KEYNOTE-028. This evidence concerns the gene ESR1 and breast cancer.